Evidence map›Paper›PMID 37328396›Full record

ArticleTrends in pharmacological sciences2023

CRISPR tiling screen reveals cancer epigenetic 'Goldilocks' state.

Aleksia Barka, Rahul M Kohli, Junwei Shi

Abstract readComment
PubMed Publisher
In one paragraph

Article in Trends in pharmacological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Aleksia BarkaGraduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Rahul M KohliDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: rkohli@pennmedicine.upenn.edu.
Junwei ShiDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: jushi@upenn.edu.
University of Pennsylvania · US

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Mapping Structure-Activity Relationships of Chemical Inhibitors via Genome-EditingDP2GM137494 · NIGMS · HARVARD UNIVERSITY · PI LIAU, BRIAN · 2019 to 2019
$2.5M
Engineering Efficient and Controllable Base EditorsR01GM138908 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI KOHLI, RAHUL MANU · 2021 to 2024
$1.9M
NIGMS NIH HHS DP2 GM137494NIGMS NIH HHS R01 GM138908NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

CRISPR tiling screens offer an efficient way to identify gain-of-function mutations in targets of cancer therapy. Recently, by utilizing these screens, Kwok et al. unexpectedly discovered mutations conferring drug addiction in lymphoma, revealing a requirement for a 'just right' window of histone methylation crucial for cancer survival.

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsNeoplasmsCRISPR-Cas SystemsEpigenesis, GeneticEpigenomicsHumansdrug addictiondrug resistancelymphomamethylation indextiling mutagenesis

Identifiers

PMID37328396
OpenAlexW4380792747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.